• Metastatic Malignant Melanoma

Dose:2 to 4.5 mg/kg/day IV for 10 days, every 4 weeksOr 850 mg/m² IV every 3 weeks

  • Hodgkin Lymphoma (as part of the ABVD regimen: Adriamycin, Bleomycin, Vinblastine, Dacarbazine)
  • Off-label: Soft tissue sarcoma, neuroendocrine tumors (rare use), other solid tumors (limited)

Dose:375 mg/m² IV on days 1 and 15 of a 28-day cycle

  • IM (lyophilized powder): 100 mg, 200 mg vials,Must be reconstituted and diluted before IV use
  • IV only — no oral formulation
  • Reconstitute with sterile water → further dilute in 5% dextrose or NS
  • Protect from light (photodegradation sensitive)
  • Infuse over 15–30 minutes
  • Use antiemetics (highly emetogenic drug)
  • Class: Alkylating agent (non-classic), triazene group
  • Mechanism of Action:
    • Prodrug → metabolized in liver (by CYP1A1, 1A2) to active MTIC → alkylates DNA → strand breakage → apoptosis
  • Cell-cycle nonspecific
  • Half-life: ~20 minutes (short)
  • Excretion: Renal (mostly as metabolites)
  • Severe nausea/vomiting (highly emetogenic)
  • Fatigue
  • Flu-like symptoms
  • Myelosuppression (neutropenia, thrombocytopenia, anemia)
  • Anorexia
  • Diarrhea
  • Hypersensitivity to dacarbazine
  • Severe bone marrow suppression
  • Pregnancy (unless life-threatening indication)
  • Active infection
  • Myelosuppressive agents: additive risk
  • Hepatotoxic drugs: increase risk of liver injury
  • Live vaccines: avoid due to immunosuppression
  • No significant CYP-mediated drug interactions

                                   Drug Status

Availability
Pregnancy
Breastfeeding
Schedule
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Dacmed 200mg Injection 1’s United Biotech Salama Pharma
Dacarzine 200mg Injection 1’s PSM Pharma PSM Pharma